Generating destination analysis
Compass Direction
Earnings IntelligenceAI-Powered
Compass Score
Key Numbers
Market Cap
$1.5B
P/E
N/A
Revenue Growth
+40.0%
Gross Margin
N/A
ROE
N/A
About Ginkgo Bioworks
Ginkgo Bioworks (DNA) is a small-cap NYSE-listed company in the biotech space, positioned as a pure-play investment vehicle for the biotech and genomics megatrend. Synthetic biology platform engineering organisms for pharma, agriculture, and industrial biotech. With a $1.5B market capitalization and no current profitability, Ginkgo Bioworks has delivered hypergrowth trajectory with revenue moving +40% over the past year.
Expert Coverage
Unlock Full DNA Analysis
Expert analysis and coverage for Ginkgo Bioworks
Upgrade to CompassFull access to 500+ ratings • $9/month
Price & Technical Analysis
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
More in Biotech & Genomics
Eli Lilly and Company
Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs.
Alnylam Pharmaceuticals
RNA interference therapeutics leader with approved treatments for rare diseases.
CRISPR Therapeutics
Pioneer of CRISPR gene-editing therapy with first approved treatment for sickle cell disease.
Beam Therapeutics
Base editing platform with differentiated gene-editing pipeline.